title: Comment re: Temozolomide preferentially depletes cancer stem cells.
authors.forename: Roberto
authors.initials: R
authors.lastname: Pallini
authors.forename: Nicola
authors.initials: N
authors.lastname: Montano
authors.forename: Luigi M
authors.initials: LM
authors.lastname: Larocca
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000473:pathology*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D005909:Glioblastoma / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D008279:Magnetic Resonance Imaging; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000473:pathology; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide